A study of serial ctDNA evaluations in HER2-positive metastatic breast cancer treated with oral anti-HER1/HER2 tyrosine kinase inhibitors by Ma et al. found that HER2 amplification related to disease progression. The gene discussed is ERBB2; the disease is breast cancer.